05:20 PM EDT, 09/10/2025 (MT Newswires) -- Personalis ( PSNL ) has partnered with a cancer team from Yale Cancer Center for a clinical trial aimed at enhancing outcomes in patients with breast cancer, it said Wednesday.

The study is funded by the Translational Breast Cancer Research Consortium.

The trial will probe whether ultra-sensitive circulating tumor DNA-guided intervention can prevent metastatic relapse and improve outcomes for patients with HR+/HER2- breast cancer, the company added.